A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jan 2018
At a glance
- Drugs Dabrafenib (Primary) ; Antineoplastics; Trametinib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 10 Jan 2018 Planned End Date changed from 30 Nov 2017 to 30 Aug 2018.
- 10 Jan 2018 Planned primary completion date changed from 30 Nov 2017 to 30 Aug 2018.
- 10 Jan 2018 Status changed from recruiting to active, no longer recruiting.